APO Research
Talk to an analyst

APO RESEARCH · REPORT

GalNAc-based Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global GalNAc-based Drug Market Outlook and Growth Opportunities 2026

29 December 2025191 pages

Choose your research edition.

Industry ResearchGalNAc-based Drug Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal GalNAc-based Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal GalNAc-based Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GalNAc-based Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal GalNAc-based Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global GalNAc-based Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for GalNAc-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for GalNAc-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for GalNAc-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the GalNAc-based Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the GalNAc-based Drug market include Suzhou Ribo Life Science Co., Ltd, Sirnaomics, Novartis, Novo Nordisk (Dicerna), Hitgen (Leaderna Therapeutics Ltd.), Silence Therapeutics, Ionis, Arrowhead and Arbutus, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global GalNAc-based Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of GalNAc-based Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents GalNAc-based Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global GalNAc-based Drug market.

GalNAc-based Drug Segment by Company

Suzhou Ribo Life Science Co., Ltd

Sirnaomics

Novartis

Novo Nordisk (Dicerna)

Hitgen (Leaderna Therapeutics Ltd.)

Silence Therapeutics

Ionis

Arrowhead

Arbutus

Alnylam Pharmaceuticals

GalNAc-based Drug Segment by Type

siRNA Based

ASO Based

GalNAc-based Drug Segment by Application

Metabolic Diseases

Neurological Diseases

Cardiovascular Diseases

Other

GalNAc-based Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global GalNAc-based Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the GalNAc-based Drug key companies, revenue, market share, and recent developments.

3. To split the GalNAc-based Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions GalNAc-based Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify GalNAc-based Drug significant trends, drivers, influence factors in global and regions.

6. To analyze GalNAc-based Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GalNAc-based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GalNAc-based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GalNAc-based Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global GalNAc-based Drug industry.

Chapter 3: Detailed analysis of GalNAc-based Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of GalNAc-based Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of GalNAc-based Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. GalNAc-based Drug Industry Trends Table 2. GalNAc-based Drug Industry Drivers Table 3. GalNAc-based Drug Industry Opportunities and Challenges Table 4. GalNAc-based Drug Industry Restraints Table 5. Global GalNAc-based Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global GalNAc-based Drug Revenue Share by Company (2021-2026) Table 7. Global GalNAc-based Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global GalNAc-based Drug Key Company Manufacturing Base & Headquarters Table 9. Global GalNAc-based Drug Company, Product Type & Application Table 10. Global GalNAc-based Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global GalNAc-based Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of siRNA Based Table 15. Significant Companies of ASO Based Table 16. Global GalNAc-based Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global GalNAc-based Drug Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global GalNAc-based Drug Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global GalNAc-based Drug Sales Value Share by Type (2021-2026) Table 20. Global GalNAc-based Drug Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Metabolic Diseases Table 22. Significant Companies of Neurological Diseases Table 23. Significant Companies of Cardiovascular Diseases Table 24. Significant Companies of Other Table 25. Global GalNAc-based Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global GalNAc-based Drug Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global GalNAc-based Drug Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global GalNAc-based Drug Sales Value Share by Application (2021-2026) Table 29. Global GalNAc-based Drug Sales Value Share by Application (2027-2032) Table 30. Global GalNAc-based Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global GalNAc-based Drug Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global GalNAc-based Drug Sales Value Share by Region (2021-2026) Table 33. Global GalNAc-based Drug Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global GalNAc-based Drug Sales Value Share by Region (2027-2032) Table 35. Global GalNAc-based Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global GalNAc-based Drug Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global GalNAc-based Drug Sales Value Market Share by Country (2021-2026) Table 38. Global GalNAc-based Drug Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global GalNAc-based Drug Sales Value Market Share by Country (2027-2032) Table 40. Suzhou Ribo Life Science Co., Ltd Company Information Table 41. Suzhou Ribo Life Science Co., Ltd Business Overview Table 42. Suzhou Ribo Life Science Co., Ltd GalNAc-based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Suzhou Ribo Life Science Co., Ltd GalNAc-based Drug Product Portfolio Table 44. Suzhou Ribo Life Science Co., Ltd Recent Development Table 45. Sirnaomics Company Information Table 46. Sirnaomics Business Overview Table 47. Sirnaomics GalNAc-based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Sirnaomics GalNAc-based Drug Product Portfolio Table 49. Sirnaomics Recent Development Table 50. Novartis Company Information Table 51. Novartis Business Overview Table 52. Novartis GalNAc-based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Novartis GalNAc-based Drug Product Portfolio Table 54. Novartis Recent Development Table 55. Novo Nordisk (Dicerna) Company Information Table 56. Novo Nordisk (Dicerna) Business Overview Table 57. Novo Nordisk (Dicerna) GalNAc-based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Novo Nordisk (Dicerna) GalNAc-based Drug Product Portfolio Table 59. Novo Nordisk (Dicerna) Recent Development Table 60. Hitgen (Leaderna Therapeutics Ltd.) Company Information Table 61. Hitgen (Leaderna Therapeutics Ltd.) Business Overview Table 62. Hitgen (Leaderna Therapeutics Ltd.) GalNAc-based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Hitgen (Leaderna Therapeutics Ltd.) GalNAc-based Drug Product Portfolio Table 64. Hitgen (Leaderna Therapeutics Ltd.) Recent Development Table 65. Silence Therapeutics Company Information Table 66. Silence Therapeutics Business Overview Table 67. Silence Therapeutics GalNAc-based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Silence Therapeutics GalNAc-based Drug Product Portfolio Table 69. Silence Therapeutics Recent Development Table 70. Ionis Company Information Table 71. Ionis Business Overview Table 72. Ionis GalNAc-based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Ionis GalNAc-based Drug Product Portfolio Table 74. Ionis Recent Development Table 75. Arrowhead Company Information Table 76. Arrowhead Business Overview Table 77. Arrowhead GalNAc-based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Arrowhead GalNAc-based Drug Product Portfolio Table 79. Arrowhead Recent Development Table 80. Arbutus Company Information Table 81. Arbutus Business Overview Table 82. Arbutus GalNAc-based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Arbutus GalNAc-based Drug Product Portfolio Table 84. Arbutus Recent Development Table 85. Alnylam Pharmaceuticals Company Information Table 86. Alnylam Pharmaceuticals Business Overview Table 87. Alnylam Pharmaceuticals GalNAc-based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Alnylam Pharmaceuticals GalNAc-based Drug Product Portfolio Table 89. Alnylam Pharmaceuticals Recent Development Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. GalNAc-based Drug Product Image Figure 2. Global GalNAc-based Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GalNAc-based Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global GalNAc-based Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. siRNA Based Image Figure 8. ASO Based Image Figure 9. Global GalNAc-based Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global GalNAc-based Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global GalNAc-based Drug Sales Value Share by Type (2021-2032) Figure 12. Metabolic Diseases Image Figure 13. Neurological Diseases Image Figure 14. Cardiovascular Diseases Image Figure 15. Other Image Figure 16. Global GalNAc-based Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global GalNAc-based Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global GalNAc-based Drug Sales Value Share by Application (2021-2032) Figure 19. Global GalNAc-based Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global GalNAc-based Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America GalNAc-based Drug Sales Value (2021-2032) & (US$ Million) Figure 22. North America GalNAc-based Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe GalNAc-based Drug Sales Value (2021-2032) & (US$ Million) Figure 24. Europe GalNAc-based Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific GalNAc-based Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific GalNAc-based Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America GalNAc-based Drug Sales Value (2021-2032) & (US$ Million) Figure 28. South America GalNAc-based Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa GalNAc-based Drug Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa GalNAc-based Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt GalNAc-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • siRNA Based
  • ASO Based
Applications
  • Metabolic Diseases
  • Neurological Diseases
  • Cardiovascular Diseases
  • Other
Companies covered
  • Suzhou Ribo Life Science Co., Ltd
  • Sirnaomics
  • Novartis
  • Novo Nordisk (Dicerna)
  • Hitgen (Leaderna Therapeutics Ltd.)
  • Silence Therapeutics
  • Ionis
  • Arrowhead
  • Arbutus
  • Alnylam Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global GalNAc-based Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global GalNAc-based Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 GalNAc-based Drug Market Dynamics
  1. 2.1 GalNAc-based Drug Industry Trends
  2. 2.2 GalNAc-based Drug Industry Drivers
  3. 2.3 GalNAc-based Drug Industry Opportunities and Challenges
  4. 2.4 GalNAc-based Drug Industry Restraints
3 GalNAc-based Drug Market by Company
  1. 3.1 Global GalNAc-based Drug Company Revenue Ranking in 2025
  2. 3.2 Global GalNAc-based Drug Revenue by Company (2021-2026)
  3. 3.3 Global GalNAc-based Drug Company Ranking (2024-2026)
  4. 3.4 Global GalNAc-based Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global GalNAc-based Drug Company Product Type and Application
  6. 3.6 Global GalNAc-based Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global GalNAc-based Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 GalNAc-based Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 GalNAc-based Drug Market by Type
  1. 4.1 GalNAc-based Drug Type Introduction
  2. 4.1.1 siRNA Based
  3. 4.1.2 ASO Based
  4. 4.2 Global GalNAc-based Drug Sales Value by Type
  5. 4.2.1 Global GalNAc-based Drug Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global GalNAc-based Drug Sales Value by Type (2021-2032)
  7. 4.2.3 Global GalNAc-based Drug Sales Value Share by Type (2021-2032)
5 GalNAc-based Drug Market by Application
  1. 5.1 GalNAc-based Drug Application Introduction
  2. 5.1.1 Metabolic Diseases
  3. 5.1.2 Neurological Diseases
  4. 5.1.3 Cardiovascular Diseases
  5. 5.1.4 Other
  6. 5.2 Global GalNAc-based Drug Sales Value by Application
  7. 5.2.1 Global GalNAc-based Drug Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global GalNAc-based Drug Sales Value by Application (2021-2032)
  9. 5.2.3 Global GalNAc-based Drug Sales Value Share by Application (2021-2032)
6 GalNAc-based Drug Regional Value Analysis
  1. 6.1 Global GalNAc-based Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global GalNAc-based Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global GalNAc-based Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global GalNAc-based Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America GalNAc-based Drug Sales Value (2021-2032)
  7. 6.3.2 North America GalNAc-based Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe GalNAc-based Drug Sales Value (2021-2032)
  10. 6.4.2 Europe GalNAc-based Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific GalNAc-based Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific GalNAc-based Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America GalNAc-based Drug Sales Value (2021-2032)
  16. 6.6.2 South America GalNAc-based Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa GalNAc-based Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa GalNAc-based Drug Sales Value Share by Country, 2025 VS 2032
7 GalNAc-based Drug Country-level Value Analysis
  1. 7.1 Global GalNAc-based Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global GalNAc-based Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global GalNAc-based Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global GalNAc-based Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt GalNAc-based Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt GalNAc-based Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt GalNAc-based Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Suzhou Ribo Life Science Co., Ltd
  2. 8.1.1 Suzhou Ribo Life Science Co., Ltd Company Information
  3. 8.1.2 Suzhou Ribo Life Science Co., Ltd Business Overview
  4. 8.1.3 Suzhou Ribo Life Science Co., Ltd GalNAc-based Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Suzhou Ribo Life Science Co., Ltd GalNAc-based Drug Product Portfolio
  6. 8.1.5 Suzhou Ribo Life Science Co., Ltd Recent Developments
  7. 8.2 Sirnaomics
  8. 8.2.1 Sirnaomics Company Information
  9. 8.2.2 Sirnaomics Business Overview
  10. 8.2.3 Sirnaomics GalNAc-based Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sirnaomics GalNAc-based Drug Product Portfolio
  12. 8.2.5 Sirnaomics Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis GalNAc-based Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis GalNAc-based Drug Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Novo Nordisk (Dicerna)
  20. 8.4.1 Novo Nordisk (Dicerna) Company Information
  21. 8.4.2 Novo Nordisk (Dicerna) Business Overview
  22. 8.4.3 Novo Nordisk (Dicerna) GalNAc-based Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novo Nordisk (Dicerna) GalNAc-based Drug Product Portfolio
  24. 8.4.5 Novo Nordisk (Dicerna) Recent Developments
  25. 8.5 Hitgen (Leaderna Therapeutics Ltd.)
  26. 8.5.1 Hitgen (Leaderna Therapeutics Ltd.) Company Information
  27. 8.5.2 Hitgen (Leaderna Therapeutics Ltd.) Business Overview
  28. 8.5.3 Hitgen (Leaderna Therapeutics Ltd.) GalNAc-based Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Hitgen (Leaderna Therapeutics Ltd.) GalNAc-based Drug Product Portfolio
  30. 8.5.5 Hitgen (Leaderna Therapeutics Ltd.) Recent Developments
  31. 8.6 Silence Therapeutics
  32. 8.6.1 Silence Therapeutics Company Information
  33. 8.6.2 Silence Therapeutics Business Overview
  34. 8.6.3 Silence Therapeutics GalNAc-based Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Silence Therapeutics GalNAc-based Drug Product Portfolio
  36. 8.6.5 Silence Therapeutics Recent Developments
  37. 8.7 Ionis
  38. 8.7.1 Ionis Company Information
  39. 8.7.2 Ionis Business Overview
  40. 8.7.3 Ionis GalNAc-based Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Ionis GalNAc-based Drug Product Portfolio
  42. 8.7.5 Ionis Recent Developments
  43. 8.8 Arrowhead
  44. 8.8.1 Arrowhead Company Information
  45. 8.8.2 Arrowhead Business Overview
  46. 8.8.3 Arrowhead GalNAc-based Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Arrowhead GalNAc-based Drug Product Portfolio
  48. 8.8.5 Arrowhead Recent Developments
  49. 8.9 Arbutus
  50. 8.9.1 Arbutus Company Information
  51. 8.9.2 Arbutus Business Overview
  52. 8.9.3 Arbutus GalNAc-based Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Arbutus GalNAc-based Drug Product Portfolio
  54. 8.9.5 Arbutus Recent Developments
  55. 8.10 Alnylam Pharmaceuticals
  56. 8.10.1 Alnylam Pharmaceuticals Company Information
  57. 8.10.2 Alnylam Pharmaceuticals Business Overview
  58. 8.10.3 Alnylam Pharmaceuticals GalNAc-based Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Alnylam Pharmaceuticals GalNAc-based Drug Product Portfolio
  60. 8.10.5 Alnylam Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst